An Invitation for Patient Representatives
With a constantly growing list of oligonucleotide therapies that are either approved by the FDA or being tested in clinical trials, these exciting research molecules-turned-therapeutic strategy are starting to lead the way in treatments for many devastating diseases. At its core, an oligonucleotide therapeutic is a short synthetic DNA or RNA that is constructed to target a specific sequence of an RNA produced by your cells, called an messengerRNA (mRNA). Whilst the concept is simple, converting this idea to an effective therapeutic required the development of changes to the properties of oligonucleotides.
We are excited to invite patient representatives to attend the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) which will be held in Munich, Germany from October 13th -16th. This conference brings together leading researchers from around the world in both Academia and Industry to foster new ideas and network, all with the focus on development of novel therapeutics.
OTS would be excited to hear from patient group representatives who would like to come and discuss the disease that they represent with our world leading researchers. Patient representatives are welcome to present a poster or simply to register and be introduced to leading oligonucleotide experts in the field.